KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Intangibles (2018 - 2026)

Twist Bioscience has reported Intangibles over the past 9 years, most recently at $13.0 million for Q1 2026.

  • Quarterly Intangibles fell 6.85% to $13.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $13.0 million through Mar 2026, down 6.85% year-over-year, with the annual reading at $13.4 million for FY2025, 7.27% down from the prior year.
  • Intangibles was $13.0 million for Q1 2026 at Twist Bioscience, down from $13.2 million in the prior quarter.
  • Over five years, Intangibles peaked at $62.5 million in Q1 2022 and troughed at $13.0 million in Q1 2026.
  • The 5-year median for Intangibles is $51.9 million (2024), against an average of $36.8 million.
  • Year-over-year, Intangibles soared 4939.76% in 2022 and then tumbled 73.57% in 2024.
  • A 5-year view of Intangibles shows it stood at $58.4 million in 2022, then decreased by 8.86% to $53.2 million in 2023, then plummeted by 73.28% to $14.2 million in 2024, then fell by 7.41% to $13.2 million in 2025, then fell by 1.26% to $13.0 million in 2026.
  • Per Business Quant, the three most recent readings for TWST's Intangibles are $13.0 million (Q1 2026), $13.2 million (Q4 2025), and $13.4 million (Q3 2025).